BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23281290)

  • 1. Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer.
    Abdolahi M; Shahbazi-Gahrouei D; Laurent S; Sermeus C; Firozian F; Allen BJ; Boutry S; Muller RN
    Contrast Media Mol Imaging; 2013; 8(2):175-84. PubMed ID: 23281290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer.
    Tse BW; Cowin GJ; Soekmadji C; Jovanovic L; Vasireddy RS; Ling MT; Khatri A; Liu T; Thierry B; Russell PJ
    Nanomedicine (Lond); 2015 Feb; 10(3):375-86. PubMed ID: 25407827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative [Fe]MRI of PSMA-targeted SPIONs specifically discriminates among prostate tumor cell types based on their PSMA expression levels.
    Sillerud LO
    Int J Nanomedicine; 2016; 11():357-71. PubMed ID: 26855574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
    Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
    Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative [Fe]MRI determination of the dynamics of PSMA-targeted SPIONs discriminates among prostate tumor xenografts based on their PSMA expression.
    Sillerud LO
    J Magn Reson Imaging; 2018 Aug; 48(2):469-481. PubMed ID: 29331081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo Molecular MRI Imaging of Prostate Cancer by Targeting PSMA with Polypeptide-Labeled Superparamagnetic Iron Oxide Nanoparticles.
    Zhu Y; Sun Y; Chen Y; Liu W; Jiang J; Guan W; Zhang Z; Duan Y
    Int J Mol Sci; 2015 Apr; 16(5):9573-87. PubMed ID: 25927579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
    Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
    J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer.
    Nagesh PKB; Johnson NR; Boya VKN; Chowdhury P; Othman SF; Khalilzad-Sharghi V; Hafeez BB; Ganju A; Khan S; Behrman SW; Zafar N; Chauhan SC; Jaggi M; Yallapu MM
    Colloids Surf B Biointerfaces; 2016 Aug; 144():8-20. PubMed ID: 27058278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging.
    Serda RE; Adolphi NL; Bisoffi M; Sillerud LO
    Mol Imaging; 2007; 6(4):277-88. PubMed ID: 17711783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate.
    Moffatt S; Papasakelariou C; Wiehle S; Cristiano R
    Gene Ther; 2006 May; 13(9):761-72. PubMed ID: 16453011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity.
    Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
    Prostate; 2010 Sep; 70(12):1286-94. PubMed ID: 20623630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
    Bander NH; Trabulsi EJ; Kostakoglu L; Yao D; Vallabhajosula S; Smith-Jones P; Joyce MA; Milowsky M; Nanus DM; Goldsmith SJ
    J Urol; 2003 Nov; 170(5):1717-21. PubMed ID: 14532761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.
    Kinoshita Y; Kuratsukuri K; Newman N; Rovito PM; Kaumaya PT; Wang CY; Haas GP
    Prostate Cancer Prostatic Dis; 2005; 8(4):359-63. PubMed ID: 16172607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of MUC1-expressing ovarian cancer by C595 monoclonal antibody-conjugated SPIONs using MR imaging.
    Shahbazi-Gahrouei D; Abdolahi M
    ScientificWorldJournal; 2013; 2013():609151. PubMed ID: 24194685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized Anti-Prostate-Specific Membrane Antigen Single-Chain Variable Fragment-Loaded Nanobubbles as a Novel Targeted Ultrasound Contrast Agent for the Diagnosis of Prostate Cancer.
    Ding Y; Cao Q; Qian S; Chen X; Xu Y; Chen J; Shen H
    J Ultrasound Med; 2020 Apr; 39(4):761-773. PubMed ID: 31702068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody.
    Muthumani K; Marnin L; Kudchodkar SB; Perales-Puchalt A; Choi H; Agarwal S; Scott VL; Reuschel EL; Zaidi FI; Duperret EK; Wise MC; Kraynyak KA; Ugen KE; Sardesai NY; Joseph Kim J; Weiner DB
    Cancer Immunol Immunother; 2017 Dec; 66(12):1577-1588. PubMed ID: 28819703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
    McDevitt MR; Barendswaard E; Ma D; Lai L; Curcio MJ; Sgouros G; Ballangrud AM; Yang WH; Finn RD; Pellegrini V; Geerlings MW; Lee M; Brechbiel MW; Bander NH; Cordon-Cardo C; Scheinberg DA
    Cancer Res; 2000 Nov; 60(21):6095-100. PubMed ID: 11085533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and characterization of an antibody-labeled super-paramagnetic iron oxide contrast agent targeting prostate cancer cells for magnetic resonance imaging.
    Bates D; Abraham S; Campbell M; Zehbe I; Curiel L
    PLoS One; 2014; 9(5):e97220. PubMed ID: 24819929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanohybride Materials Based on Magnetite-Gold Nanoparticles for Diagnostics of Prostate Cancer: Synthesis and In Vitro Testing.
    Machulkin AE; Garanina AS; Zhironkina OA; Beloglazkina EK; Zyk NV; Savchenko AG; Kotelyanskii VE; Mazhuga AG
    Bull Exp Biol Med; 2016 Sep; 161(5):706-710. PubMed ID: 27704352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells.
    Zare H; Rajabibazl M; Rasooli I; Ebrahimizadeh W; Bakherad H; Ardakani LS; Gargari SL
    Int J Biol Markers; 2014 Jun; 29(2):e169-79. PubMed ID: 24425321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.